Navigation Links
'Possible Key to Alzheimer Medication'
Date:10/26/2010

'Possible Key to Alzheimer Medication' -- LEIDEN, Netherlands, October 26, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

'Possible Key to Alzheimer Medication'

 

LEIDEN, Netherlands, October 26, 2010 /PRNewswire/ -- Dutch researchers have discovered a possible key which might result in a medicine for Alzheimer's disease. "We have found brain cells which become extra active at a time when there are still no visible symptoms of the disease. Nevertheless, people are already ill", says brain researcher Dick Swaab. "It would be fantastic if we could simulate this activation process through medicines once the disease has progressed." The findings of the Dutch scientists, under the auspices of research institute TI Pharma, are due to be published in the reputable scientific magazine Brain.

Scientists examined the brain tissue of 49 deceased patients, in various stages of the disease. In the very earliest stage of the disease, patients did not appear to have any memory impairments or other symptoms of Alzheimer's disease. Under the microscope, however, signs of Alzheimer's are visible. Swaab: "The brain itself appears to compensate for the disease process; nearly 500 genes in the front part of the parahippocampal cortex then become extra active. These genes ensure that nerve cells are better able to communicate with each other, allowing people to continue to function well. As soon as these genes become less active, the memory impairments become apparent."

According to Swaab, this discovery is an important step on the road to finding effective medication. "We see these temporarily active genes as a pointer to a medicine. Once the disease has progressed to a more advanced stage, we can see whether we can reactivate the brain cells using medicines." Swaab adds that a medicine for Alzheimer's will only be a possibility for future generations.

Alzheimer's is the most common cause of dementia. Between sixty and seventy percent of patients suffer from this form of dementia. In Alzheimer's disease, the nerve cells in the brain and the connections between these cells break down, preventing the brain from functioning well. There are an estimated quarter of a million patients in the Netherlands; this number will double in the next forty years.

The research to which among others neuroscientists Dick Swaab, Joost Verhaagen and Koen Bossers from the Netherlands Institute for Neurosciences contribute is funded by Top Instituut Pharma. Other partners are the Netherlands Brain Bank, DNage and health care organization Abbott.

About Top Institute Pharma

Top Institute Pharma (TI Pharma) is a public-private partnership in which the academic and business world work together on innovative, multidisciplinary research targeted toward the improvement of the development of socially valuable medicines. The project portfolio is based on the clinical areas as described in the "Priority Medicines" report from the World Health Organization (WHO). These projects create knowledge that is important for the better, faster and less expensive development of valuable new medicines. For more information, please visit http://www.tipharma.com.


'/>"/>
SOURCE Top Institute Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
2. Denser, more powerful computer chips possible with plasmonic lenses that fly
3. Self-powered devices possible, says Texas A&M researcher
4. Bio-Matrix Scientific Group CEO Tells Wall Street Transcript That Positive Cash Flow Is Possible in 09; New Stem Cell Banking Facility Is Growth Vehicle Over the Next Two Years, Says CEO in Exclusive News Interview
5. New security and medical sensor devices made possible by metallic nanostructures
6. MMR Offers Free Surgical Masks to Call Attention to Importance of Personal Health Records in Preparing for Possible Swine Flu Pandemic
7. Practice makes perfect -- motor memory possible for neuroprosthetic control
8. NeoStem, Inc. is Certified by the State of New York as a Qualified Emerging Technology Company and Notifies Investors of Possible Tax Credit of up to 20%
9. Brazilian Sugarcane Industry Association Stresses Need for Brazils Government to Announce Ethanol Import Tariff Cut as Soon as Possible
10. BioSpec Global Solutions Inc. Enters into talks with possible Chinese partner
11. Researchers stretch a lackluster material into a possible electronics revolution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... ... leading supplier of Semantic Graph Database technology has been recognized As “ Best ... by Corporate America Magazine. , “At Corporate America, it’s our priority to showcase ...
(Date:2/3/2016)... , Feb. 3, 2016   ViaCyte, ... with the first pluripotent stem cell-derived islet replacement ... in clinical-stage development, today announced that ViaCyte and ... Companies of Johnson & Johnson, have agreed to ... into ViaCyte.  The agreement provides ViaCyte with an ...
(Date:2/3/2016)... Denmark , Feb. 3, 2016 Ascendis ... biotechnology company that applies its innovative TransCon technology to ... present at an upcoming investor conference.Event:2016 Leerink Partners Global ... NY Date:  , Wednesday, February 10, 2016 Time:  ... www.ascendispharma.com . --> An audio webcast ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a world-leading supplier ... the North American healthcare market. , Aerocom Healthcare, LLC will be based in ... will provide new pneumatic tube systems or expand existing systems within the U.S. ...
Breaking Biology Technology:
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
(Date:1/27/2016)... CHESTER, Ohio , Jan. 27, 2016  Rite ... supplier based in West Chester, Ohio ... their award winning service staff, based in ... technical capacity and ability to provide modifications, installations and ... John Dovalina , CEO of PLUS, commented, "PLUS has ...
(Date:1/22/2016)... , January 22, 2016 /PRNewswire/ ... announced the addition of the  "Global ... their offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ...
Breaking Biology News(10 mins):